BioMarin Pharmaceutical Inc. is just days away from filing its ground-breaking hemophilia gene therapy with the FDA, and looks odds-on to gain approval by mid-2020.
Valoctocogene roxaparvovec (valrox for short) is at the head of a wave of new gene therapies for the inherited condition and has demonstrated the ability to virtually eliminate all bleeds and the